Targeting minimal residual disease: a path to cure?
Name
Manilis-NRC_Weinstock_1511378928_v4.11.27.17.pdf
Description
Main article
Size
259.44 KB
Format
Adobe PDF
Checksum (MD5)
c51ec12329acc2cd75045a5fc1dd556d
Author(s)
Luskin, Marlise R.
Murakami, Mark A.
Weinstock, David M.
Manalis, Scott R
Date Issued
January 2018
Journal
Nature Reviews Cancer
Publisher
Nature Publishing Group
Citation
Luskin, Marlise R., Mark A. Murakami, Scott R. Manalis, and David M. Weinstock. “Targeting Minimal Residual Disease: a Path to Cure?” Nature Reviews Cancer 18, no. 4 (January 29, 2018): 255–263. doi:10.1038/nrc.2017.125.
Version
Author's final manuscript
Abstract
Therapeutics that block kinases, transcriptional modifiers, immune checkpoints and other biological vulnerabilities are transforming cancer treatment. As a result, many patients achieve dramatic responses, including complete radiographical or pathological remission, yet retain minimal residual disease (MRD), which results in relapse. New functional approaches can characterize clonal heterogeneity and predict therapeutic sensitivity of MRD at a single-cell level. Preliminary evidence suggests that iterative detection, profiling and targeting of MRD would meaningfully improve outcomes and may even lead to cure.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Mechanical Engineering
Program in Media Arts and Sciences (Massachusetts Institute of Technology)
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/nrc.2017.125
